Floatz logo

Dipyridamole

Portal Hypertension

Northern Jiangsu People's HospitalSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Portal Hypertension cohort.

Asset / SponsorPhaseRating
CARVEDILOL
West China Hospital
Phase 4BBB
SIMVASTATIN
Kafrelsheikh University
Phase 4BBB
Apsolol
West China Hospital
Phase 4BBB
Apixaban
Asian Institute Of Medical Sciences
Phase 4BB
WARFARIN
Northern Jiangsu People's Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Dipyridamole is also rated in:

venous thromboembolismActive
BB
Indicative · Phase 4
71 / 100
View asset →
brain ischemiaDormant
BB
Indicative · Phase 4
68 / 100
View asset →
arteriosclerosis disorderDormant
BB
Indicative · Phase 4
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →